The global Enzyme
Linked Immunosorbent Assay (ELISA) Market, by Method (Direct ELISA,
Indirect ELISA, Sandwich ELISA, and Competitive ELISA), by Application (Vaccine
Development, Immunology, Diagnostics, Toxicology, Drug Monitoring &
Pharmaceutical Industry & Transplantation), By Technology
(Chemiluminescent, Colorimetric, & Fluorescent), and by Region (North
America, Latin America, Europe, Asia Pacific, Middle East, and Africa) was
valued at US$ 1,583.4 million in 2016 and is projected to exhibit a CAGR of
5.1% over the forecast period (2017 – 2025). Enzyme-Linked Immunosorbent Assay
(ELISA) Market is expected to gain significant traction over the forecast
period, owing to the launch of novel assays and increasing demand for cost
efficient tools due to increasing incidence of chronic infectious diseases and
cancer. For instance, According to a National Cancer Institute, 2016, an
estimated 16.8 million new cases of cancer were diagnosed in the U.S., with
around 595,690 deaths from the disease. The number of people suffering from
cancer is expected to rise to 19 million by 2024.
Technological advancements in
ELISA test kits are expected to foster growth of global Enzyme Linked Immunosorbent
Assay (ELISA) Market Extensive research and development in the field of
immunoassay and diagnostics is leading to increasing applications and novel
approaches for incorporation of ELISA in various medical fields. This has
resulted in expansion of the range of Enzyme Linked Immunosorbent Assay (ELISA)
products used in clinical and medical approaches. For instance, Inova
Diagnostics, in November 2016, received U.S. FDA approval for QUANTA Lite, a
Calprotectin Extended range of quantitative ELISA assay that aids in the
diagnosis of Inflammatory Bowel Disease (IBD) and helps to differentiate IBD
from Irritable Bowel Syndrome (IBS). Moreover, a recent test is developed by
Center for Infection and Immunity at University of Columbia in March 2018,
extends a window for accurate detection of Zika infection, which is complex
with molecular diagnostics procedures.
* The sample copy includes: Report Summary, Table of Contents,
Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copy
of this report: https://www.coherentmarketinsights.com/insight/request-sample/1505
The new ZIKV-NS2B-concat ELISA is
a faster, less expensive blood test, and clinical tool for accurate detection
of Zika from weeks to months after onset of infection facilitating a powerful
tool for the clinicians to make quick decisions for their patients. In July
2015, Bio-Rad Laboratories, Inc. received the U.S. Food and Drug Administration
pre-market approval for BioPlex 2200 HIV Ag-Ab assay, which is the company's
fifth generation HIV diagnostic test that produced efficient diagnostic test
results for HIV.
Browse 42 Market Data Tables and
36 Figures spread through 170 Pages and in-depth TOC on “Enzyme Linked
Immunosorbent Assay (ELISA) Market”- by Method (Direct ELISA, Indirect ELISA,
Sandwich ELISA and Competitive ELISA), by Application (Vaccine Development,
Immunology, Diagnostics, Toxicology, Drug Monitoring & Pharmaceutical
Industry & Transplantation), By Technology (Chemiluminescent, Colorimetric,
& Fluorescent), and by Region (North America, Latin America, Europe, Asia
Pacific, Middle East, and Africa) - Global Forecast to 2025.
The market players are focused
towards expansion of their product portfolio and geographic reach by adoption
of inorganic strategies such as mergers and acquisitions to maintain their
positions in the market. For instance, in March 2017, Thermo Fisher Scientific,
Inc. acquired Core Informatics and added it to analytical Instruments segment
to strengthen its existing informatics solutions and bio production offerings.
Furthermore, the company players are also focusing on research and development
for introducing novel ELISA assays and test kits in to the market to stand out
and retain their positions in the market. For instance, in August 2016, ALPCO introduced
new and improved, highly specific Total Adiponectin and HMW & Total
Adiponectin ELISAs, this colorimetric assays provides researchers with the confidence
to measure adiponectin.
Browse Research
Report: https://www.coherentmarketinsights.com/market-insight/enzyme-linked-immunosorbent-assay-market-1505
Key Takeaways of Enzyme Linked
Immunosorbent Assay (ELISA) Market:
The global Enzyme Linked
Immunosorbent Assay (ELISA) Market is expected to exhibit a CAGR of 5.1% over
the forecast period, owing to increasing incidence of infectious diseases
coupled with rising adoption of cost-effective diagnostic solutions
Among method segment, the
indirect ELISA segment dominates the global ELISA market, owing to high
sensitivity and flexibility offered by the method for determination of
concentration of a target substance in a sample
Among technology, diagnostics
segment held dominant position in the global ELISA market, owing to potential
of the assay to detect wide variety of disease in human and screen large number
of samples
Among region, North America is
expected to dominate the global Enzyme Linked Immunosorbent Assay (ELISA) Market,
owing to introduction of innovative solutions in market to overcome issues
faced by the clinical facilities and other users
The key players operating in
global Enzyme Linked Immunosorbent Assay (ELISA) Market include Bio-Rad
Laboratories, Inc., Enzo Life Sciences, Inc., Thermo Fisher Scientific, Inc.,
Biomerieux S.A., Alpco, BioLegand, Inc., Zeus Scientific, Inc., and Shenzhen
YHLO Biotech Co., Ltd.
Buy-Now this research
report: https://www.coherentmarketinsights.com/insight/buy-now/1505
About
Coherent Market Insights:
Coherent
Market Insights is a prominent market research and consulting firm offering
action-ready syndicated research reports, custom market analysis, consulting
services, and competitive analysis through various recommendations related to
emerging market trends, technologies, and potential absolute dollar opportunity.
Contact
Us:
mailto:sales@coherentmarketinsights.com
U.S.
Office:
Name: Mr. Shah
Coherent
Market Insights 1001 4th Ave,
# 3200
Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN
: +050-5539-1737
No comments:
Post a Comment